Ibrutinib and atrial fibrillation as cardiotoxicity – A new safety warning that impacts overall survival
Open Access
- 10 March 2022
- journal article
- Published by Scientific Scholar in International Journal of Molecular and Immuno Oncology
Abstract
Atrial fibrillation is a well recognized side effects of several drugs. However it is ignored since most studies have failed to show that it impacts survival adversely. This is not the case with ibrutinib, especially amongst patients with pre-existing cardiac morbidities. In this article, we provide practical consensus guidelines for cancer patients being commenced on therapy with ibrutinib.Keywords
This publication has 20 references indexed in Scilit:
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLLThe New England Journal of Medicine, 2018
- Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström MacroglobulinemiaJournal of Clinical Oncology, 2018
- Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective studyJournal of Hematology & Oncology, 2018
- Management of Atrial Fibrillation in Patients on Ibrutinib: A Cleveland Clinic ExperienceCureus, 2018
- Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency ProfileThe Journal of pharmacology and experimental therapeutics, 2017
- Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid LeukemiaJournal of Medicinal Chemistry, 2015
- Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 studyThe Lancet, 2015
- Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signalingBlood, 2014
- Phosphoinositide 3-Kinase p110α Is a Master Regulator of Exercise-Induced Cardioprotection and PI3K Gene Therapy Rescues Cardiac DysfunctionCirculation: Heart Failure, 2012
- Drug-induced atrial fibrillationJournal of Invasive Cardiology, 2004